About VGX Pharmaceuticals
VGX Pharmaceuticals is a company based in Blue Bell (United States) founded in 2002 was acquired by Inovio Pharmaceuticals in July 2008. VGX Pharmaceuticals has raised $4.5 million across 4 funding rounds from investors including NIH, Korean Development Bank and Inovio Pharmaceuticals. VGX Pharmaceuticals operates in a competitive market with competitors including Novavax, Dyne Therapeutics, CureVac, Immunomic Therapeutics and Codagenix, among others.
- Headquarter Blue Bell, United States
-
Sectors
Healthcare
-
Phone
Locked
-
Website
Locked
-
Social
Locked
-
Annual Revenue
Not available
-
Net Profit
Not available
-
EBITDA
Not available
-
Total Equity Funding
$4.5 M (USD)
in 4 rounds
-
Latest Funding Round
$23.5 M (USD), Grant
Oct 01, 2008
-
Investors
NIH
& 3 more
-
Employee Count
Not available
-
Acquired by
Inovio Pharmaceuticals
(Jul 07, 2008)
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Funding Insights of VGX Pharmaceuticals
VGX Pharmaceuticals has successfully raised a total of $4.5M across 4 strategic funding rounds. The most recent funding activity was a Grant round of $23.5 million completed in October 2008. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in VGX Pharmaceuticals
VGX Pharmaceuticals has secured backing from 4 investors, including institutional and venture fund investors. Prominent investors backing the company include NIH, Korean Development Bank and Inovio Pharmaceuticals.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
-
|
Locked | Locked | Locked | |
|
Drug discovery services are provided to the biopharma sector.
|
Locked | Locked | Locked | |
|
Development financing and commercial banking are provided in South Korea.
|
Locked | Locked | Locked |
Investor details for VGX Pharmaceuticals
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by VGX Pharmaceuticals
Investment portfolio details for VGX Pharmaceuticals
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - VGX Pharmaceuticals
Detailed financials for VGX Pharmaceuticals
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Vgx Pharmaceuticals Comparisons
Peer comparison for VGX Pharmaceuticals
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of VGX Pharmaceuticals
VGX Pharmaceuticals operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Novavax, Dyne Therapeutics, CureVac, Immunomic Therapeutics and Codagenix, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Novel vaccines are developed using nanoparticle and matrix adjuvant technology.
|
|
| Locked | Locked | Locked |
Nucleic acid therapies for rare diseases are developed.
|
|
| Locked | Locked | Locked |
mRNA-based therapeutics against cancer and infectious diseases are developed.
|
|
| Locked | Locked | Locked |
Immunomic Therapeutics is engaged in developing nucleic acid immunotherapy platforms.
|
|
| Locked | Locked | Locked |
Live-attenuated viral vaccines are developed using proprietary SAVE technology.
|
|
| Locked | Locked | Locked |
Therapeutic vaccines for cancer and infectious diseases are developed.
|
Detailed competitors of VGX Pharmaceuticals
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Vgx Pharmaceuticals
Complete news archive for VGX Pharmaceuticals
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about VGX Pharmaceuticals
VGX Pharmaceuticals was founded in 2002 and raised its 1st funding round 1 year after it was founded.
VGX Pharmaceuticals is headquartered in Blue Bell, United States. It is registered at Blue Bell, Pennsylvania, United States.
VGX Pharmaceuticals is a funded company, having raised a total of $4.5M across 4 funding rounds to date.
VGX Pharmaceuticals was established in 2002 in Blue Bell, United States, within the biotechnology sector. Focus was placed on DNA-based vaccines targeting infectious diseases and cancers, alongside related devices. Key clinical programs encompassed Pennvax-B for HIV prevention, VGX-1027 for inflammatory conditions, VGX-3100 for cervical cancer treatment, and the Cellectra electroporator for DNA delivery. Operations concluded with a merger into Inovio Pharmaceuticals in July 2008.
VGX Pharmaceuticals's top competitors include Dyne Therapeutics, Scancell and Novavax.
VGX Pharmaceuticals has 4 investors. Key investors include NIH, Korean Development Bank, Inovio Pharmaceuticals, and BioAdvance.